Market Overview

UPDATE: Cantor Fitzgerald Raises PT to $8 on Ironwood Pharmaceuticals; Maintains Sell

Related IRWD
Ironwood Presents IW-9179 Phase IIa Data At American College Of Gastroenterology 2014 Annual Scientific Meeting
Ironwood Pharmaceuticals Announces Initiation Of Phase II Trial Of Linaclotide In Adult Patients With Opioid-Induced Constipation

Cantor Fitzgerald reiterated its Sell rating on Ironwood Pharmaceuticals, (NASDAQ: IRWD) but raised its price target from $7 to $8 ahead of the Linaclotide PDUFA.

Cantor Fitzgerald said, "We reiterate our SELL rating going into the Linaclotide PDUFA: We remain cautiously optimistic about a first pass approval (we estimate 70% probability) but maintain that the stock is overvalued and could sell off even under a best- case scenario (since investors may play the event and then exit the stock post- approval due to lack of pending positive catalysts)."

Ironwood Pharmaceuticals closed at $12.29 on Friday.

Latest Ratings for IRWD

DateFirmActionFromTo
Sep 2014Cowen & CompanyDowngradesOutperformMarket Perform
Aug 2014Leerink SwannMaintainsMarket Perform
Jul 2014Furey ResearchInitiates Coverage onBuy

View More Analyst Ratings for IRWD
View the Latest Analyst Ratings

Posted-In: Cantor FitzgeraldAnalyst Color Price Target Reiteration Intraday Update Analyst Ratings

 

Related Articles (IRWD)

Around the Web, We're Loving...

Get Benzinga's Newsletters